The Lancet Haematology
更新于 14 分钟前
近期历史最近 100 条记录
| 2024-05-09 | [Review] Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management | Kai Rejeski, Michael D Jain, Nirali N Shah, Miguel-Angel Perales, Marion Subklewe | |
| 2024-05-04 | [Articles] Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study | Timothy J Craig, Donald S Levy, Avner Reshef, William R Lumry, Inmaculada Martinez-Saguer, Joshua S Jacobs, William H Yang, Bruce Ritchie, Emel Aygören-Pürsün, Paul K Keith, Paula Busse, Henrike Feuersenger, Mihai Alexandru Bica, Iris Jacobs, Ingo Pragst, | |
| 2024-05-04 | [News] 50th Annual Meeting of the EBMT | Yaiza del Pozo Martín | |
| 2024-05-01 | [Articles] Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial | Banu Aygun, Adam Lane, Luke R Smart, Brígida Santos, Léon Tshilolo, Thomas N Williams, Peter Olupot-Olupot, Susan E Stuber, George Tomlinson, Teresa Latham, Russell E Ware, REACH Investigators | |
| 2024-05-01 | [Comment] Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa | Najibah A Galadanci, Julie Kanter | |
| 2024-04-25 | [Articles] Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial | Elizabeth O'Donnell, Clifton Mo, Andrew J Yee, Omar Nadeem, Jacob Laubach, Jacalyn Rosenblatt, Nikhil Munshi, Shonali Midha, Diana Cirstea, Pavlina Chrysafi, Nora Horick, Paul G Richardson, Noopur Raje | |
| 2024-04-25 | [Comment] Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation? | Natalie Scott Callander | |
| 2024-04-18 | [Corrections] Correction to Lancet Haematol 2024; 11: e27–37 | | |
| 2024-04-09 | [Viewpoint] Methodological challenges in the development of endpoints for myelofibrosis clinical trials | Giovanni Barosi, Ayalew Tefferi, Naseema Gangat, Natasha Szuber, Alessandro Rambaldi, Olatoyosi Odenike, Nicolaus Kröger, Nico Gagelmann, Moshe Talpaz, Hagop Kantarjian, Robert Peter Gale | |
| 2024-04-05 | [Articles] Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial | Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva-Maria Wagner-Drouet, Lutz P Müller, Christoph Schmid, Stefan W Krause, Wolfgang Bethge, Edgar Jost, Uwe Platzbecker, Stefan A Klein, Jörg Schubert, Judith Niederland, Martin Kaufmann, Kerstin Schäfer- | |
| 2024-04-05 | [Comment] Transplant without salvage: cut out the middleman | Arjun Datt Law, Jonas Ingemar Mattsson | |
| 2024-03-29 | [Articles] Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study | Natalie S Grover, George Hucks, Marcie L Riches, Anastasia Ivanova, Dominic T Moore, Thomas C Shea, Mary Beth Seegars, Paul M Armistead, Kimberly A Kasow, Anne W Beaven, Christopher Dittus, James M Coghill, Katarzyna J Jamieson, Benjamin G Vincent, Willia | |
| 2024-03-29 | [Comment] The value of anti-CD30 CAR T cells in Hodgkin lymphoma | Marianne Veyri | |
| 2024-03-28 | [Articles] Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial | Mark T Gladwin, Victor R Gordeuk, Payal C Desai, Caterina Minniti, Enrico M Novelli, Claudia R Morris, Kenneth I Ataga, Laura De Castro, Susanna A Curtis, Fuad El Rassi, Hubert James Ford, Thomas Harrington, Elizabeth S Klings, Sophie Lanzkron, Darla Lile | |
| 2024-03-28 | [Comment] Riociguat shows remarkable safety but underwhelming activity in patients with sickle cell disease | Emily M Limerick, Courtney D Fitzhugh | |
| 2024-03-28 | [Articles] First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial | Xiao-Peng Tian, Jun Cai, Yi Xia, Yu-Chen Zhang, Liang Wang, Pan-Pan Liu, Hui-Qiang Huang, Ya-Jun Li, Hui Zhou, Zhi-Ming Li, Jing Yang, Li-Qiang Wei, Qi-Hua Zou, Ying Huang, Jun Li, Li Ling, Wen-Long Zhong, Qing-Qing Cai | |
| 2024-03-28 | [Comment] First-line immunochemotherapy for extranodal natural killer/T cell lymphoma | Shu-Nan Qi, Ye-Xiong Li | |
匿名用户只展示最新 100 条榜单历史，更多历史数据请登录后查看，支持时光机按天筛选
Sponsors
